Terlipressin Versus Somatostatin/Octreotide on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage (TORCH): A Retrospective Multicenter Observational Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,682
- 试验地点
- 14
- 主要终点
- Incidence of ICA-AKI and kidney function damage in cirrhotic patients with acute gastrointestinal bleeding
研究概览
简要总结
Terlipressin and somatostatin/octreotide are the first-line choices for the treatment of acute variceal bleeding in liver cirrhosis. Acute kidney injury can develop in patients presenting with acute variceal bleeding. On the other hand, evidence suggests that terlipressin can reverse hepatorenal syndrome. It has been hypothesized that terlipressin can protect the renal function in cirrhotic patients with acute variceal bleeding, except for control of bleeding.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Cirrhotic patients who were admitted between January 2010 and December
- •A diagnosis of acute gastrointestinal bleeding.
- •Patients who received terlipressin or somatostatin/octreotide.
- •Age or sex was not limited.
- •Use of endoscopy was not limited.
- •Comorbidity was not limited.
- •Malignancy was not limited.
排除标准
- •Renal parenchymal diseases.
- •Absence of baseline serum creatinine.
- •Absence of serum creatinine 3-5 days after terlipressin or somatostatin/octreotide.
- •Duration of terlipressin or somatostatin/octreotide was less 3 days.
- •Patients who underwent transjugular intrahepatic portosystemic shunt.
- •Patients who underwent surgical shunt, splenectomy with or without devascularization, or liver transplantation.
研究组 & 干预措施
Terlipressin group
Cirrhotic patients with acute gastrointestinal bleeding received terlipressin with or without somatostatin/octreotide.
干预措施: Terlipressin (Drug)
Somatostatin/Octreotide group
Cirrhotic patients with acute gastrointestinal bleeding received somatostatin and/or octreotide without terlipressin.
干预措施: Somatostatin (Drug)
Somatostatin/Octreotide group
Cirrhotic patients with acute gastrointestinal bleeding received somatostatin and/or octreotide without terlipressin.
干预措施: Octreotide (Drug)
结局指标
主要结局
Incidence of ICA-AKI and kidney function damage in cirrhotic patients with acute gastrointestinal bleeding
时间窗: Through study completion, an average of 1-2 weeks
ICA-AKI and kidney function damage
Effect of ICA-AKI and kidney function damage on in-hospital mortality of cirrhotic patients with acute gastrointestinal bleeding
时间窗: Through study completion, an average of 1-2 weeks
In-hospital mortality
Effect of terlipressin on the in-hospital mortality of cirrhotic patients with acute gastrointestinal bleeding with ICA-AKI and kidney function damage
时间窗: Through study completion, an average of 1-2 weeks
In-hospital mortality associated with ICA-AKI and kidney function damage
次要结局
未报告次要终点
研究者
Xingshun Qi
Principal Investigator
General Hospital of Shenyang Military Region